{
    "id": 24967,
    "fullName": "EGFR - RAD51",
    "impact": "fusion",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "EGFR-RAD51 results from the fusion of EGFR and RAD51, demonstrating activation of downstream signaling pathways, MAPK and PI3K, transformation activity in culture, and increased colony formation (PMID: 27102076). EGFR-RAD51 has been identified in lung cancer (PMID: 27102076, PMID: 31064887).",
            "references": [
                {
                    "id": 6404,
                    "pubMedId": 27102076,
                    "title": "EGFR Fusions as Novel Therapeutic Targets in Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27102076"
                },
                {
                    "id": 15289,
                    "pubMedId": 31064887,
                    "title": "Effectiveness of EGFR-TKIs in a Patient with Lung Adenocarcinoma Harboring an EGFR-RAD51 Fusion.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31064887"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 1956,
        "geneSymbol": "EGFR",
        "terms": [
            "EGFR",
            "ERBB",
            "ERBB1",
            "HER1",
            "mENA",
            "NISBD2",
            "PIG61"
        ]
    },
    "variant": "EGFR - RAD51",
    "createDate": "08/01/2016",
    "updateDate": "06/07/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 5888,
                "geneSymbol": "RAD51",
                "terms": [
                    "RAD51",
                    "BRCC5",
                    "FANCR",
                    "HRAD51",
                    "HsRad51",
                    "HsT16930",
                    "MRMV2",
                    "RAD51A",
                    "RECA"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 15924,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Tarceva (erlotinib) treatment resulted in a partial response in a patient with non-small cell lung carcinoma harboring EGFR-RAD51, demonstrating decreased tumor size after one month of treatment and stable disease after 5 months of treatment (PMID: 29290255).",
            "molecularProfile": {
                "id": 25735,
                "profileName": "EGFR - RAD51"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 12085,
                    "pubMedId": 29290255,
                    "title": "EGFR-RAD51 fusion variant in lung adenocarcinoma and response to erlotinib: A case report.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29290255"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7542,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EGFR-RAD51 demonstrated sensitivity to treatment with Erbitux (cetuximab) in culture, resulting in decreased cell viability (PMID: 27102076).",
            "molecularProfile": {
                "id": 25735,
                "profileName": "EGFR - RAD51"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6404,
                    "pubMedId": 27102076,
                    "title": "EGFR Fusions as Novel Therapeutic Targets in Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27102076"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17318,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Gilotrif (afatinib) treatment resulted in progression-free survival over 6 months in a patient with lung adenocarcinoma harboring EGFR-RAD51 (PMID: 29472054).",
            "molecularProfile": {
                "id": 25735,
                "profileName": "EGFR - RAD51"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15369,
                    "pubMedId": 29472054,
                    "title": "EGFR-RAD51 Fusion: A Targetable Partnership Originated from the Tumor Evolution?",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29472054"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7540,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EGFR-RAD51 demonstrated sensitivity to treatment with Gilotrif (afatinib) in culture, resulting in decreased cell viability and inhibition of downstream MAPK and PI3K signaling (PMID: 27102076).",
            "molecularProfile": {
                "id": 25735,
                "profileName": "EGFR - RAD51"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6404,
                    "pubMedId": 27102076,
                    "title": "EGFR Fusions as Novel Therapeutic Targets in Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27102076"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17317,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, icotinib treatment resulted in progression-free survival over 15 months in a patient with lung adenocarcinoma harboring EGFR-RAD51 (PMID: 31064887).",
            "molecularProfile": {
                "id": 25735,
                "profileName": "EGFR - RAD51"
            },
            "therapy": {
                "id": 769,
                "therapyName": "Icotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15289,
                    "pubMedId": 31064887,
                    "title": "Effectiveness of EGFR-TKIs in a Patient with Lung Adenocarcinoma Harboring an EGFR-RAD51 Fusion.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31064887"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7541,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EGFR-RAD51 demonstrated some sensitivity to treatment with Tagrisso (osimertinib) in culture, resulting in decreased cell viability (PMID: 27102076).",
            "molecularProfile": {
                "id": 25735,
                "profileName": "EGFR - RAD51"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6404,
                    "pubMedId": 27102076,
                    "title": "EGFR Fusions as Novel Therapeutic Targets in Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27102076"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7538,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, three patients with lung adenocarcinoma harboring EGFR-RAD51 demonstrated partial responses as indicated by tumor regression, when treated with Tarceva (erlotinib) (PMID: 27102076).",
            "molecularProfile": {
                "id": 25735,
                "profileName": "EGFR - RAD51"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6404,
                    "pubMedId": 27102076,
                    "title": "EGFR Fusions as Novel Therapeutic Targets in Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27102076"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 25735,
            "profileName": "EGFR - RAD51",
            "profileTreatmentApproaches": [
                {
                    "id": 10517,
                    "name": "EGFR Inhibitor (Pan)",
                    "profileName": "EGFR - RAD51"
                },
                {
                    "id": 10520,
                    "name": "EGFR Inhibitor 3rd gen",
                    "profileName": "EGFR - RAD51"
                },
                {
                    "id": 10521,
                    "name": "HER inhibitor (Pan)",
                    "profileName": "EGFR - RAD51"
                },
                {
                    "id": 10518,
                    "name": "EGFR Inhibitor 1st gen",
                    "profileName": "EGFR - RAD51"
                },
                {
                    "id": 10519,
                    "name": "EGFR Inhibitor 2nd gen",
                    "profileName": "EGFR - RAD51"
                },
                {
                    "id": 10505,
                    "name": "Cetuximab",
                    "profileName": "EGFR - RAD51"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}